Technology | Hemodynamic Monitoring Systems

Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its QMAPP hemodynamic monitoring system.

Home September 18, 2017
Home
Technology | Computed Tomography (CT)

Hitachi Healthcare Americas Inc. announced it has attained U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Supria True64 computed tomography (CT) system.

Home September 15, 2017
Home
Technology | SPECT Imaging

September 15, 2017 — Philips highlighted its newest solution for nuclear cardiology, CardioMD IV, at the American ...

Home September 15, 2017
Home
News | Cardiac Diagnostics

September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic ...

Home September 14, 2017
Home
News | Hypertension

Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently in the European Journal of Preventive Cardiology.

Home September 14, 2017
Home
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.
Feature | Cath Lab

September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials ...

Home September 14, 2017
Home
News | Angiography

The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease which can result in the loss of a limb. To help minimize amputations among their patient population, Capel Surgical Clinic & Vascular Center in Greenwood, Miss., uses advanced X-ray technology to restore blood flow in occluded arteries. Capel Surgical Clinic also uses the Ultimax-i FPD multipurpose system from Toshiba Medical, a Canon Group company, for interventional procedures, diagnostic angiograms and aortagrams.

Home September 14, 2017
Home
Videos | Structural Heart Occluders

Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Sidra ...

Home September 13, 2017
Home
News | Peripheral Artery Disease (PAD)

Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from Sept. 11 – 14, 2017, applying advanced technologies and deep clinical insights to address peripheral vascular needs. With the addition of its recent acquisition, Spectranetics, Philips will for the first time highlight its expanded portfolio of interventional X-ray systems, advanced catheters for measurement and therapy, clinical informatics and services, including its Philips Azurion image-guided therapy platform, intravascular ultrasound (IVUS), Phoenix atherectomy system and Spectranetics' Stellarex drug-coated balloon.

Home September 13, 2017
Home
News | Drug-Eluting Balloons

Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of peripheral artery disease (PAD) in the upper leg — specifically, in the superficial femoral arteries (SFA) and popliteal arteries. Before Medtronic can begin commercialization, it must partner with Japanese MHLW to gain reimbursement to ensure broader access to the therapy.

Home September 13, 2017
Home
News | Peripheral Artery Disease (PAD)

A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour System for treating long-segment (>25 cm) blockages in the femoropopliteal artery. The data were presented as a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA 17), Sept. 11-14 in Las Vegas. DETOUR I trial results were presented by Sean Lyden, M.D., chairman of the department of Vascular Surgery at Cleveland Clinic.

Home September 13, 2017
Home
News | Cardiac Diagnostics

Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack, according to a research letter published in the Journal of the American College of Cardiology.

Home September 12, 2017
Home
News | Cardiac Diagnostics

September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, according ...

Home September 12, 2017
Home
News | Pharmaceuticals

September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in ...

Home September 12, 2017
Home
News | ESC

September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressively ...

Home September 12, 2017
Home
Subscribe Now